Want to see SE:ACE full AI Analyst Report?
Top Page
Ascelia Pharma AB
(ACE)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.62
▼(-80.54% Downside)
Action:Upgraded
Date:07/07/26
The score is primarily held down by weak financial performance (no revenue, continued large losses and cash burn), despite low leverage. Technicals also detract, with the stock in a pronounced downtrend (well below all major moving averages) and negative MACD, even though it appears oversold on RSI. Valuation provides limited support due to negative earnings and no dividend data.
Positive Factors
Low financial leverage
Very low reported debt-to-equity (~0.01) materially reduces near-term default risk and interest burden. This structural strength preserves strategic optionality: management can prioritize clinical/regulatory milestones or pursue partnerships without immediate debt pressures, extending strategic flexibility.
Negative Factors
No revenue base
The company remains development-stage with no product revenue and large recurring losses (TTM net loss ~71m). Structurally, absence of revenue means viability and growth depend on achieving regulatory approval and successful commercialization or continued external funding, creating durable execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Very low reported debt-to-equity (~0.01) materially reduces near-term default risk and interest burden. This structural strength preserves strategic optionality: management can prioritize clinical/regulatory milestones or pursue partnerships without immediate debt pressures, extending strategic flexibility.
Read all positive factors
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr86.53M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)0.37
Revenue GrowthN/A
EPS Growth51.40%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.25
Revenue Forecast (FY)kr89.63M
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical tr...
How the Company Makes Money
null...
Ascelia Pharma AB Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -888.00K | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -68.94M | -73.24M | -67.69M | -108.56M | -132.06M | -128.42M |
| Net Income | -70.90M | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | ||||||
| Total Assets | 96.87M | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 33.89M | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 689.00K | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 13.95M | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 82.92M | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | ||||||
| Free Cash Flow | -71.25M | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -71.19M | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | -57.00K | -57.00K | 0.00 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 48.23M | 48.21M | 115.19M | -936.00K | -1.10K | 184.87M |
Ascelia Pharma AB Technical Analysis
Negative
3.17
Price Trends
2.80
Negative
2.92
Negative
2.98
Negative
Market Momentum
-0.51
Positive
19.35
Positive
1.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 2.52, above the 50-day MA of 2.80, and above the 200-day MA of 2.98, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 19.35 is Positive, neither overbought nor oversold. The STOCH value of 1.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | kr563.89M | 3.15 | 81.19% | ― | ― | ― | |
53 Neutral | kr404.14M | -3.40 | -16.51% | ― | ― | 22.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr217.39M | 0.89 | -16.90% | ― | -72.49% | ― | |
48 Neutral | kr272.10M | -3.17 | -51.35% | ― | ― | 9.40% | |
48 Neutral | kr32.07M | -0.34 | -186.13% | ― | ― | 57.42% | |
42 Neutral | kr86.53M | -1.14 | -79.60% | ― | ― | 51.40% |
* Healthcare Sector Average
SE:ACE
Ascelia Pharma AB
0.67
-3.55
-84.03%
SE:XBRANE
Xbrane Biopharma AB
10.70
-18.03
-62.75%
SE:ISOFOL
Isofol Medical AB
0.78
-0.10
-11.83%
SE:GUARD
Guard Therapeutics International AB
1.40
-17.20
-92.46%
SE:IMMU
Immunicum AB
6.46
-0.88
-11.99%
SE:CANTA
Cantargia AB
2.05
0.82
66.88%
Ascelia Pharma AB Corporate Events
Ascelia Pharma Receives FDA Complete Response Letter on Orviglance NDA
Jul 3, 2026
Ascelia Pharma AB, a Malmö-based biotech company focused on orphan oncology treatments for rare cancer-related conditions, is advancing a pipeline led by its drug candidates Orviglance and Oncoral. Listed on Nasdaq Stockholm under ticker ACE,...
Ascelia Pharma Bolsters Orviglance Franchise with New Patent Filing
Jun 30, 2026
Ascelia Pharma has filed a new patent application covering packaging and manufacturing innovations for its first-in-class liver imaging drug Orviglance, designed to improve usability for patients and healthcare professionals. The anticipated paten...
Ascelia Showcases Orviglance MRI Data at ESGAR 2026 Amid FDA Review
Jun 9, 2026
Ascelia Pharma said new clinical data for its manganese-based oral MRI contrast agent Orviglance are being presented today at the ESGAR 2026 radiology congress in Montpellier, France. The oral and poster presentations, based on re-analyses of two ...
Ascelia Pharma Nears FDA Decision on Orviglance and Bolsters Finances for Partnering Push
May 12, 2026
Ascelia Pharma reports that FDA review of its New Drug Application for Orviglance is progressing on schedule ahead of the July 3 PDUFA decision date, supported by nine clinical studies, including the pivotal Phase 3 SPARKLE trial showing significa...
Ascelia Pharma AGM Backs Incentive Plan but Rejects Share Issue Mandate
May 4, 2026
Ascelia Pharma AB’s annual general meeting on 4 May 2026 approved the 2025 accounts and decided to carry forward SEK 13.4 million without paying a dividend, while granting discharge from liability to the board and CEO. Shareholders re-electe...
Ascelia Pharma Expands Share Capital After Directed New Issue
Apr 30, 2026
Ascelia Pharma AB has increased its registered number of shares and votes following a directed new issue of ordinary shares completed in April 2026. As of 30 April 2026, the company has a total of 134,569,246 shares outstanding, comprising 133,535...
Ascelia Pharma Raises SEK 20 Million in Directed Share Issue Ahead of Orviglance Milestone
Apr 23, 2026
Ascelia Pharma has completed a directed share issue of 6,666,666 new ordinary shares at SEK 3 per share, raising SEK 20 million from a group of investors including existing shareholders Salenia AB and Mats Thorén. The move, done at roughly a ...
Ascelia Pharma Eyes Transformative 2026 With Orviglance FDA Review
Apr 9, 2026
Ascelia Pharma is positioning itself in the orphan oncology space with imaging and chemotherapy products targeting underserved patient groups. The company’s lead asset, Orviglance, addresses an estimated USD 800 million annual market for saf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.